Latest Medtech News

Medtech M&A roared back in 2025, with deal value, spin‑offs, and portfolio reshaping all accelerating—and 2026 already continuing the trend.

After a muted 2023–2024, medtech dealmaking decisively rebounded in 2025, both in scale and in strategic clarity.

One of the most important shifts in 2025 was the normalization of spin‑offs and divestitures as a core lever of portfolio strategy, not a one‑off response to activist pressure.

Looking into 2026, Bain argues that enduring softer valuations will heighten competition for high‑quality assets, forcing acquirers to be explicit about where they can “outperform the next‑best owner.” That means articulating a clear value‑creation thesis—scale advantages, superior go‑to‑market capabilities, or unique strategic fit—before deals are signed, not retrofitted afterwards.

After medical device M&A picked up last year, 2026 is off to a busy start. Boston Scientific’s planned $14.5 billion acquisition of Penumbra, a company that makes thrombectomy and embolization devices, was the largest purchase so far this year.

In another multibillion-dollar deal, Danaher announced plans this month to buy patient monitoring firm Masimo.

Several medtech firms have also announced major divestitures in the past year. Some notable ones to watch include BD’s planned $17.5 billion sale of its biosciences and diagnostics businesses, Medtronic’s planned spinoff of its diabetes business into a publicly traded company, and Johnson &Johnson’s planned divestiture of its orthopedics segment.